TC
KERX

TFS Capital’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

TFS Capital’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-418,788
Closed -$3.13M – 1727
2013
Q2 		$3.13M Buy
+418,788
New +$3.27M 0.13% 205

Other funds holding KERX

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

TFS Capital's KERX Position: Q3 2013 in Review

TFS Capital sold out of Keryx Biopharmaceuticals Inc (KERX) in Q3 2013, closing a stake of 418,788 shares — an estimated $3.13M sold.

TFS Capital first reported a position in KERX in Q2 2013 and held it in 1 quarter. The position peaked at $3.13M in Q2 2013. 110 funds tracked by Wall St. Rank hold KERX as of Q3 2013.

  • TFS Capital reported no remaining Keryx Biopharmaceuticals Inc position as of Q3 2013 after selling out during the quarter.
  • TFS Capital sold 418,788 Keryx Biopharmaceuticals Inc shares in Q3 2013, an estimated $3.13M.
  • TFS Capital first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 1 quarter.
  • TFS Capital's Keryx Biopharmaceuticals Inc position peaked at $3.13M in Q2 2013.
  • 110 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q3 2013.

Based on TFS Capital's 13F filing for Q3 2013, filed 5 Nov 2013.